Lazaar Aili L
University of Pennsylvania Medical Center, Pulmonary, Allergy and Critical Care Division, 852 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA.
Curr Opin Mol Ther. 2003 Feb;5(1):81-9.
Genentech, Novartis and Tanox have co-developed Genentech's anti-IgE humanized monoclonal antibody omalizumab for the treatment of allergic rhinitis and asthma. The antibody is currently undergoing phase II clinical trials for allergic rhinitis in Canada and phase III clinical trials for both indications in Japan. Omalizumab is at the pre-registration stage for both indications in the US, New Zealand, Switzerland and Western Europe, and is currently registered for both indications in Australia.
基因泰克、诺华和Tanox共同研发了基因泰克的抗IgE人源化单克隆抗体奥马珠单抗，用于治疗过敏性鼻炎和哮喘。该抗体目前正在加拿大进行过敏性鼻炎的II期临床试验，并在日本针对这两种适应症进行III期临床试验。奥马珠单抗在美国、新西兰、瑞士和西欧针对这两种适应症均处于预注册阶段，目前在澳大利亚已针对这两种适应症获批注册。
